ST吉药(300108) - 2024 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net loss attributable to shareholders for 2024 to be between 500 million and 850 million CNY, compared to a loss of 349.31 million CNY in the previous year[4]. - The projected operating revenue for 2024 is estimated to be between 320 million and 360 million CNY, down from 346.11 million CNY in the previous year[4]. - The net asset at the end of 2024 is expected to be between -830 million and -1.18 billion CNY, compared to -280.67 million CNY at the end of the previous year[4]. Reasons for Financial Changes - The increase in net loss is primarily due to provisions for credit impairment losses and asset impairment losses[7]. - The company's equity attributable to shareholders is projected to remain negative due to failure to complete restructuring by December 31, 2024, and ongoing financial difficulties[7]. Financial Reporting and Communication - The financial data presented is preliminary and has not been audited by the accounting firm[5]. - The company has communicated with the accounting firm regarding the earnings forecast, and there are no disagreements[6]. - Detailed financial data for 2024 will be disclosed in the annual report[8]. - The company emphasizes the importance of accurate and complete information in its announcements[2]. Investor Advisory - Investors are advised to exercise caution and be aware of investment risks due to the company's financial situation[8].